Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. 詳細を表示
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.8901 | -24.5149156939 | 7.71 | 7.78 | 5.765 | 10058721 | 6.90580377 | CS |
4 | -2.1101 | -26.6090794451 | 7.93 | 8.15 | 5.765 | 7916788 | 7.2932442 | CS |
12 | -4.3801 | -42.9421568627 | 10.2 | 12.505 | 5.765 | 7252126 | 8.83422378 | CS |
26 | -2.9201 | -33.4107551487 | 8.74 | 12.505 | 5.765 | 6588715 | 9.28512594 | CS |
52 | -3.0801 | -34.6078651685 | 8.9 | 18.33 | 5.765 | 7174940 | 10.6282187 | CS |
156 | -9.1301 | -61.07090301 | 14.95 | 18.73 | 3.21 | 5466050 | 9.11624837 | CS |
260 | -20.3001 | -77.7186064319 | 26.12 | 54.2081 | 3.21 | 4034482 | 12.82225512 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約